Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Rizzoli

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Experimental Hematology|November 27, 2012
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion moleculesMarina Bolzoni, Paola Storti, Sabrina Bonomini, et al.
Haematologica|November 4, 2006
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survivalNicola Giuliani, Sabrina Bonomini, Paola Romagnani, et al.
Blood|May 10, 2005
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myelomaLori A Ehrlich, Ho Yeon Chung, Irene Ghobrial, et al.
Cancer Research|August 16, 2008
CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesionsNicola Giuliani, Gina Lisignoli, Simona Colla, et al.
Blood|March 21, 2007
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patientsNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Blood|October 7, 2003
Do human myeloma cells directly produce basic FGF?Simona Colla, Francesca Morandi, Mirca Lazzaretti, et al.
British Journal of Haematology|May 10, 2007
MDR1 polymorphism influences the outcome of multiple myeloma patientsGabriele Buda, Valentina Maggini, Sara Galimberti, et al.
Leukemia Research|May 22, 2007
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphismsValentina Maggini, Gabriele Buda, Sara Galimberti, et al.
Blood|October 24, 2002
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone diseaseNicola Giuliani, Simona Colla, Roberto Sala, et al.
Journal of Cellular Physiology|April 15, 2009
Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix proteinGina Lisignoli, Katia Codeluppi, Katia Todoerti, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Experimental Hematology|November 27, 2012
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion moleculesMarina Bolzoni, Paola Storti, Sabrina Bonomini, et al.
Haematologica|November 4, 2006
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survivalNicola Giuliani, Sabrina Bonomini, Paola Romagnani, et al.
Blood|May 10, 2005
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myelomaLori A Ehrlich, Ho Yeon Chung, Irene Ghobrial, et al.
Cancer Research|August 16, 2008
CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesionsNicola Giuliani, Gina Lisignoli, Simona Colla, et al.
Blood|March 21, 2007
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patientsNicola Giuliani, Francesca Morandi, Sara Tagliaferri, et al.
Blood|October 7, 2003
Do human myeloma cells directly produce basic FGF?Simona Colla, Francesca Morandi, Mirca Lazzaretti, et al.
British Journal of Haematology|May 10, 2007
MDR1 polymorphism influences the outcome of multiple myeloma patientsGabriele Buda, Valentina Maggini, Sara Galimberti, et al.
Leukemia Research|May 22, 2007
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphismsValentina Maggini, Gabriele Buda, Sara Galimberti, et al.
Blood|October 24, 2002
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone diseaseNicola Giuliani, Simona Colla, Roberto Sala, et al.
Journal of Cellular Physiology|April 15, 2009
Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix proteinGina Lisignoli, Katia Codeluppi, Katia Todoerti, et al.
Pageof 5